Clinical Trials › NCT07361094
RecruitingPhase 1
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Sponsored by Beijing Boren Hospital
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 12
Target enrollment
Nov 2025
Start date
Jun 2028
Expected completion
Interventions / Treatments
Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
Conditions studied
Relapsed/Refractory Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 1 trials
Browse all Phase 1 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.